期刊
ORGANIC PROCESS RESEARCH & DEVELOPMENT
卷 16, 期 5, 页码 967-975出版社
AMER CHEMICAL SOC
DOI: 10.1021/op200346g
关键词
-
Doxercalciferol (1 alpha-hydroxyvitamin D2) is a commercially approved vitamin D derivative used to treat chronic kidney disease (CKD) patients whose kidneys cannot metabolically introduce a hydroxyl group at C1. A new process for the production of doxercalciferol from ergocalciferol was developed using a continuous photoisomerization of a known vitamin D intermediate as the key step, thus circumventing the limitations of batch photoisomerization processes. Doxercalciferol is produced in an overall yield of about 10% from ergocalciferol.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据